Actovegin® reduces PMA-induced inflammation on human cells

Area of Science:

• Immunology
• Pharmacology

Background:

• Peripheral blood mononuclear cells (PBMCs) play a crucial role in inflammatory responses.
• Phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS) are common stimuli used to induce inflammation in vitro.
• Actovegin® is a drug with potential anti-inflammatory properties.

Purpose of the Study:

• To investigate the effect of Actovegin® on PMA- and LPS-induced human PBMCs.
• To assess Actovegin®'s impact on cytokine secretion and reactive oxygen species (ROS) production.

Main Methods:

• Human PBMCs were exposed to Actovegin® with or without PMA or LPS.
• Cytokine concentrations (TNF-α, IL-1beta, IL-6, IL-10) in supernatants were measured.
• Reactive oxygen species (ROS) production was assessed using a ROS-Glo™ assay.

Main Results:

• PMA and LPS significantly increased cytokine secretion from PBMCs.
• Actovegin® pre-treatment significantly decreased IL-1beta secretion induced by PMA.
• Actovegin® did not alter IL-1beta production induced by LPS.
• Actovegin® did not affect TNF-α, IL-6, or IL-10 secretion in the context of PMA or LPS stimulation.

Conclusions:

• Actovegin® demonstrates an ability to reduce PMA-induced IL-1beta release and ROS production in PBMCs.
• These findings support the potential therapeutic role of Actovegin® in managing inflammatory conditions, such as athletic injuries.